Fifteen vaccinia virus (VV) recombinants derived from VV strains Praha, LIVP and DD (i.e. Dryvax Wyeth vaccine-derived) and expressing genes for S, preS2-S or c antigens of hepatitis B virus (HBV) were tested in monkey CV-1 cells and human diploid LEP cells. The production of infectious virus was found to be alike in all the recombinants and parental viruses as well. However, several recombinants produced markedly lesser amounts of S and preS2 antigens in LEP cells than in CV-1 cells. This reduction was independent of the parental virus used. There was, however, a relationship between the production of preS2 in CV-1 cells and the production of S and preS2 antigens in LEP cells; in general, recombinants efficiently inducing preS2 antigen formation in CV-1 cells produced markedly reduced amounts of S and preS2 antigens in LEP cells. Reduction of HBV antigen production in LEP cells was not apparent in recombinants expressing only S or c antigens of HBV, and the production of c antigen by double recombinants was not influenced by simultaneous expression of preS2 and S. The various recombinants also differed in the ratio of S:preS2 antigen formation. This difference seemed to be associated with the length of the untranslated leader sequence preceding preS2 but not with the parental virus or cell type used. The titers of antibodies against S and preS2 antigens induced in mice immunized with different recombinants differed markedly. The differences in the ratio of S:preS2 antigen production in vitro were not reflected in vivo by S:preS2 antibody ratio.

Department of Experimental Virology Institute of Hematology and Blood Transfusion Prague The Czech Republic

Zobrazit více v PubMed

Gene Expr. 1991 May;1(2):117-25 PubMed

J Virol. 1987 Apr;61(4):1286-90 PubMed

Acta Virol. 1988 Sep;32(5):409-16 PubMed

Proc Natl Acad Sci U S A. 1980 Aug;77(8):4549-53 PubMed

J Virol. 1984 Mar;49(3):857-64 PubMed

Acta Virol. 1969 May;13(3):209-15 PubMed

Virology. 1962 Sep;18:9-18 PubMed

Nature. 1979 Dec 6;282(5739):575-9 PubMed

Proc Natl Acad Sci U S A. 1984 Jan;81(1):193-7 PubMed

Arch Virol. 1991;121(1-4):29-41 PubMed

Arch Virol. 1990;112(3-4):181-93 PubMed

Nature. 1983 Apr 7;302(5908):490-5 PubMed

Acta Virol. 1991 Sep;35(5):413-22 PubMed

J Virol. 1986 Nov;60(2):337-44 PubMed

Arch Virol. 1990;113(3-4):283-9 PubMed

J Virol. 1982 Apr;42(1):100-5 PubMed

J Virol. 1987 Mar;61(3):683-92 PubMed

FEBS Lett. 1985 Jun 3;185(1):208-12 PubMed

Proc Natl Acad Sci U S A. 1986 Dec;83(24):9338-42 PubMed

J Med Virol. 1986 Oct;20(2):111-25 PubMed

Mol Cell Biol. 1987 Jul;7(7):2538-44 PubMed

Virology. 1986 Jul 30;152(2):285-97 PubMed

Nature. 1979 May 3;279(5708):43-7 PubMed

Proc Natl Acad Sci U S A. 1982 Aug;79(16):4927-31 PubMed

Vaccine. 1989 Feb;7(1):53-9 PubMed

Antitumor activity and immunogenicity of recombinant vaccinia virus expressing HPV 16 E7 protein SigE7LAMP is enhanced by high-level coexpression of IGFBP-3